

1. Shaban A, Al Kasab S, Chalhoub RM, Bass E, Maier I, Psychogios MN, et al. Mechanical thrombectomy for large vessel occlusion strokes beyond 24 hours. *J Neurointerv Surg*. 2023. Epub 2023/01/03. doi: 10.1136/jnis-2022-019372. PubMed PMID: 36593118.
2. Vitanza NA, Ronsley R, Choe M, Henson C, Breedt M, Barrios-Anderson A, et al. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. *Neoplasia*. 2023;36:100870. Epub 2023/01/05. doi: 10.1016/j.neo.2022.100870. PubMed PMID: 36599192; PubMed Central PMCID: PMC9823206.
3. Larkin CJ, Thirunavu VM, Nahi SL, Roumeliotis AG, Shlobin NA, Kandula V, et al. Analysis of socioeconomic and demographic factors on post-treatment outcomes for metastatic spinal tumors. *Clin Neurol Neurosurg*. 2023;225:107581. Epub 2023/01/07. doi: 10.1016/j.clineuro.2022.107581. PubMed PMID: 36608466.
4. Picetti E, Catena F, Abu-Zidan F, Ansaloni L, Armonda RA, Bala M, et al. Early management of isolated severe traumatic brain injury patients in a hospital without neurosurgical capabilities: a consensus and clinical recommendations of the World Society of Emergency Surgery (WSES). *World J Emerg Surg*. 2023;18(1):5. Epub 2023/01/10. doi: 10.1186/s13017-022-00468-2. PubMed PMID: 36624517; PubMed Central PMCID: PMC9830860.
5. Alvarado-Dyer R, Aguilera S, Chesnut RM, Videtta W, Fischer D, Jibaja M, et al. Managing Severe Traumatic Brain Injury Across Resource Settings: Latin American Perspectives. *Neurocrit Care*. 2023;38(2):229-34. Epub 2023/01/13. doi: 10.1007/s12028-022-01670-5. PubMed PMID: 36635495; PubMed Central PMCID: PMC9836742.
6. Butler SH, Loeser JD. Multidisciplinary Pain Management: A Tale of Two Outcomes. *Anesthesiology*. 2023;138(3):312-5. Epub 2023/01/14. doi: 10.1097/aln.0000000000004444. PubMed PMID: 36637501.
7. Abecassis IJ, Almallouhi E, Chalhoub R, Kasab SA, Bass E, Ding D, et al. Outcomes after endovascular mechanical thrombectomy for low compared to high National Institutes of Health Stroke Scale (NIHSS): A multicenter study. *Clin Neurol Neurosurg*. 2023;225:107592. Epub 2023/01/20. doi: 10.1016/j.clineuro.2023.107592. PubMed PMID: 36657358.
8. Pan J, Bonow RH, Temkin N, Robinson EF, Sekhar LN, Levitt MR, et al. Incidence and Risk Model of Venous Thromboembolism in Patients with Aneurysmal Subarachnoid Hemorrhage. *World Neurosurg*. 2023;172:e418-e27. Epub 2023/01/20. doi: 10.1016/j.wneu.2023.01.045. PubMed PMID: 36657716.
9. Rawat V, Eastman CL, Amaradhi R, Banik A, Fender JS, Dingleline RJ, et al. Temporal Expression of Neuroinflammatory and Oxidative Stress Markers and Prostaglandin E2 Receptor EP2 Antagonist Effect in a Rat Model of Epileptogenesis. *ACS Pharmacol Transl Sci*. 2023;6(1):128-38. Epub 2023/01/20. doi: 10.1021/acsptsci.2c00189. PubMed PMID: 36654746; PubMed Central PMCID: PMC9841781 and R.D. are founders of, and have equity in, Pyrefin Inc., which has licensed EP2 technology from Emory University in which T.G., R.D., and R.A. are inventors.
10. Ham CH, Kwon WK, Moon HJ, Kim JH, Park YK, Hofstetter CP. Use of prophylactic perioperative antibiotics for lumbar spinal fusions: A nationwide population-based cohort study. *J Infect Public Health*. 2023;16(3):354-60. Epub 2023/01/23. doi: 10.1016/j.jiph.2023.01.005. PubMed PMID: 36682101.
11. Stein MB, Jain S, Parodi L, Choi KW, Maihofer AX, Nelson LD, et al. Polygenic risk for mental disorders as predictors of posttraumatic stress disorder after mild traumatic brain injury. *Transl Psychiatry*. 2023;13(1):24. Epub 2023/01/25. doi: 10.1038/s41398-023-02313-9. PubMed PMID: 36693822; PubMed Central PMCID: PMC9873804 Boehringer-Ingelheim, EmpowerPharm, Engrail Therapeutics, Genentech/Roche, GW Pharma, Janssen, Jazz Pharmaceuticals, and NeuroTrauma Sciences; as well as stock options from Oxeia Biopharmaceuticals and EpiVario, all outside the submitted work. Dr. Manley discloses grants from the United States Department of Defense, TRACK-TBI Precision Medicine (Grant # W81XWH-18-2-0042), and TRACK-TBI NETWORK (Grant # W81XWH-15-9-0001); and the National Football League (NFL) Scientific Advisory Board – TRACK-TBI LONGITUDINAL. United States Department of Energy supports Dr. Manley for a precision medicine collaboration. He has received an unrestricted gift from the NFL to the UCSF Foundation to support the research efforts of the TRACK-TBI NETWORK. He has also received funding from NeuroTrauma Sciences LLC for TRACK-TBI data curation efforts. Amy Markowitz receives funding from the Department of Defense TBI Endpoints Development Initiative (Grant #W81XWH-14-2-0176) and TRACK-TBI NETWORK (Grant # W81XWH-15-9-0001). Ms. Markowitz also receives salary support from the United States Department of Energy precision medicine collaboration. Dr. Diaz-Arrastia received personal fees and research funding from Neural Analytics Inc and travel reimbursement from Brain Box Solutions Inc outside the submitted work. Dr. Mukherjee received grants from GE Healthcare and nonfinancial support from GE-NFL Head Health Initiative outside the submitted work; in addition, Dr. Mukherjee had a patent for USPTO no. 62/269,778 pending. Dr. Rosand consulted for Takeda Pharmaceuticals, outside the scope of the submitted work. Dr. Choi was supported in part by funding from the National Institute of Mental Health (K08MH127413) and a NARSAD Brain and Behavior Foundation Young

Investigator Award.

12. Luciano M, Holubkov R, Williams MA, Malm J, Nagel S, Moghekar A, et al. Placebo-Controlled Effectiveness of Idiopathic Normal Pressure Hydrocephalus Shunting: A Randomized Pilot Trial. *Neurosurgery*. 2023;92(3):481-9. Epub 2023/01/27. doi: 10.1227/neu.0000000000002225. PubMed PMID: 36700738; PubMed Central PMCID: PMC9904195.
13. Kunapaisal T, Moore A, Theard MA, King MA, Chesnut RM, Vavilala MS, et al. Experience with clinical cerebral autoregulation testing in children hospitalized with traumatic brain injury: Translating research to bedside. *Front Pediatr*. 2022;10:1072851. Epub 2023/01/28. doi: 10.3389/fped.2022.1072851. PubMed PMID: 36704136; PubMed Central PMCID: PMC9871541.
14. Ju Wang JD, Doherty D, Ramirez JM, Chen M. Central sleep apnea in patients with pontine tegmental cap dysplasia treated with supplemental oxygen: a case report. *J Clin Sleep Med*. 2023;19(4):843-9. Epub 2023/01/29. doi: 10.5664/jcsm.10452. PubMed PMID: 36708265; PubMed Central PMCID: PMC9871390.
15. Liu Q, Li J, Zhang Y, Leng X, Mossa-Basha M, Levitt MR, et al. Association of calcium channel blockers with lower incidence of intracranial aneurysm rupture and growth in hypertensive patients. *J Neurosurg*. 2023;1-10. Epub 2023/01/29. doi: 10.3171/2022.12.Jns222428. PubMed PMID: 36708539.
16. Mahan MA, Prasse T, Kim RB, Sivakanthan S, Kelly KA, Kashlan ON, et al. Full-endoscopic spine surgery diminishes surgical site infections - a propensity score-matched analysis. *Spine J*. 2023;23(5):695-702. Epub 2023/01/29. doi: 10.1016/j.spinee.2023.01.009. PubMed PMID: 36708928.
17. Rundfeldt C, Klein P, Boison D, Rotenberg A, D'Ambrosio R, Eastman C, et al. Preclinical pharmacokinetics and tolerability of a novel meglumine-based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. *Epilepsia*. 2023;64(4):888-99. Epub 2023/01/29. doi: 10.1111/epi.17520. PubMed PMID: 36708090.
18. Huff A, Karlen-Amarante M, Oliveira LM, Ramirez JM. Postinspiratory complex acts as a gating mechanism regulating swallow-breathing coordination and other laryngeal behaviors. *bioRxiv*. 2023. Epub 2023/01/31. doi: 10.1101/2023.01.18.524513. PubMed PMID: 36712111; PubMed Central PMCID: PMC9882227.
19. Ambartsumyan L, Patel D, Kapavarapu P, Medina-Centeno RA, El-Chammas K, Khlevner J, et al. Evaluation and Management of Postsurgical Patient With Hirschsprung Disease Neurogastroenterology & Motility Committee: Position Paper of North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN). *J Pediatr Gastroenterol Nutr*. 2023;76(4):533-46. Epub 2023/02/01. doi: 10.1097/mpg.0000000000003717. PubMed PMID: 36720091.
20. Ironside N, Chen CJ, Chalhoub RM, Kellogg RT, Ding D, Maier I, et al. Risk factors and predictors of intracranial hemorrhage after mechanical thrombectomy in acute ischemic stroke: insights from the Stroke Thrombectomy and Aneurysm Registry (STAR). *J Neurointerv Surg*. 2023. Epub 2023/02/02. doi: 10.1136/jnis-2022-019513. PubMed PMID: 36725360.
21. Breakey RWF, Mercan E, van de Lande LS, Sidpra J, Birgfeld C, Lee A, et al. Two-Center Review of Posterior Vault Expansion following a Staged or Expectant Treatment of Crouzon and Apert Craniosynostosis. *Plast Reconstr Surg*. 2023;151(3):615-26. Epub 2023/02/03. doi: 10.1097/prs.0000000000000925. PubMed PMID: 36730425.
22. Massenburg BB, Mercan E, Shepard E, Birgfeld CB, Susarla SM, Lee A, et al. Morphometric Outcomes of Nonsyndromic Sagittal Synostosis following Open Middle and Posterior Cranial Vault Expansion. *Plast Reconstr Surg*. 2023;151(4):844-54. Epub 2023/02/03. doi: 10.1097/prs.00000000000010008. PubMed PMID: 36729760.
23. Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. *Genes Dev*. 2023;37(3-4):86-102. Epub 2023/02/03. doi: 10.1101/gad.349803.122. PubMed PMID: 36732025; PubMed Central PMCID: PMC9871390.
24. Nguyen AN, Purnell CA, Mercan E, Lee A, Birgfeld CB, Susarla SM, et al. Cranial Shape Changes in Nonsyndromic Unilateral Lambdoid Synostosis after Open Posterior Vault Remodeling. *Plast Reconstr Surg*. 2023;152(1):155-65. Epub 2023/02/03. doi: 10.1097/prs.00000000000010228. PubMed PMID: 36727694.
25. Hawryluk GWJ, Citerio G, Hutchinson P, Kolias A, Meyfroidt G, Robba C, et al. Correction: Intracranial pressure: current perspectives on physiology and monitoring. *Intensive Care Med*. 2023;49(3):384. Epub 2023/02/04. doi: 10.1007/s00134-023-06977-1. PubMed PMID: 36735001.
26. Kotheeranurak V, Liawrungrueang W, Quillo-Olvera J, Siepe CJ, Li ZZ, Lokhande PV, et al. Full-Endoscopic Lumbar Discectomy Approach Selection: A Systematic Review and Proposed Algorithm. *Spine (Phila Pa 1976)*. 2023;48(8):534-44. Epub 2023/02/07. doi: 10.1097/brs.0000000000004589. PubMed PMID: 36745468.
27. Boerwinkle VL, Schor NF, Slomine BS, Molteni E, Ramirez JM, Rasmussen L, et al. Proceedings of the First Pediatric Coma and Disorders of Consciousness Symposium by the Curing Coma Campaign, Pediatric Neurocritical

- Care Research Group, and NINDS: Gearing for Success in Coma Advancements for Children and Neonates. *Neurocrit Care*. 2023;38(2):447-69. Epub 2023/02/10. doi: 10.1007/s12028-023-01673-w. PubMed PMID: 36759418; PubMed Central PMCID: PMC9910782.
28. Shenoy VS, Sekhar LN. Microsurgical Clipping of a Ruptured Wide-Neck Basilar Tip Aneurysm by an Extended Transsylvian Transcavernous Approach: 2-Dimensional Operative Video. *World Neurosurg*. 2023;173:1-2. Epub 2023/02/13. doi: 10.1016/j.wneu.2023.02.024. PubMed PMID: 36775234.
  29. Loeser JD. Reply to Manhapra. *Pain*. 2023;164(3):e175. Epub 2023/02/14. doi: 10.1097/j.pain.0000000000002832. PubMed PMID: 36779560.
  30. Chesnut RM, Temkin N, Videtta W, Lujan S, Petroni G, Pridgeon J, et al. Testing the Impact of Protocolized Care of Patients With Severe Traumatic Brain Injury Without Intracranial Pressure Monitoring: The Imaging and Clinical Examination Protocol. *Neurosurgery*. 2023;92(3):472-80. Epub 2023/02/16. doi: 10.1227/neu.0000000000002251. PubMed PMID: 36790211; PubMed Central PMCID: PMC991058870.
  31. Jafari A, Adappa ND, Anagnos VJ, Campbell RG, Castelnovo P, Chalian A, et al. Orbital resection by intranasal technique (ORBIT): A new classification system for reporting endoscopically resectable primary benign orbital tumors. *Int Forum Allergy Rhinol*. 2023. Epub 2023/02/23. doi: 10.1002/alr.23141. PubMed PMID: 36808854.
  32. McAvoy M, Satyanarayan Shenoy V, Miller C, Feroze A, Moe KS, Sekhar LN. Operative Technique and Complication Management in a Case of Giant Esthesioneuroblastoma Resected by a Combined Transcranial and Endonasal Endoscopic Approach: Technical Case Report. *Oper Neurosurg (Hagerstown)*. 2023;24(6):e449-e53. Epub 2023/02/23. doi: 10.1227/ons.0000000000000649. PubMed PMID: 36804514.
  33. Bollo RJ, Gross PH, Rocque BG, Browd SR, Raskin JS, Leonard JR, et al. A multicenter initiative to reduce intrathecal baclofen pump surgical site infection: a Cerebral Palsy Research Network quality improvement project. *J Neurosurg Pediatr*. 2023;31(5):444-52. Epub 2023/02/26. doi: 10.3171/2023.1.Peds22368. PubMed PMID: 36840731.
  34. Khaing ZZ, Chen JY, Safarians G, Ezubeik S, Pedroncelli N, Duquette RD, et al. Clinical Trials Targeting Secondary Damage after Traumatic Spinal Cord Injury. *Int J Mol Sci*. 2023;24(4). Epub 2023/02/26. doi: 10.3390/ijms24043824. PubMed PMID: 36835233; PubMed Central PMCID: PMC9960771.
  35. Sen RD, Martinez V, Eaton J, Holdefer RN, Ellenbogen RG. Intraoperative neuromonitoring for pediatric Chiari decompression: when is it useful? *Neurosurg Focus*. 2023;54(3):E9. Epub 2023/03/02. doi: 10.3171/2022.12.Focus22632. PubMed PMID: 36857781.
  36. Paulson VA, Liu YJ, Fang H, Browd SR, Hauptman JS, Wright J, et al. Infantile ZFTA Fusion-Positive Tumor of the Posterior Fossa: Molecular Tumor Board. *JCO Precis Oncol*. 2023;7:e2200226. Epub 2023/03/03. doi: 10.1200/po.22.00226. PubMed PMID: 36862968; PubMed Central PMCID: PMC9910309551 manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/po/author-center](http://ascopubs.org/po/author-center). Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
  37. Perfetti DC, Rogers-LaVanne MP, Satin AM, Yap N, Khan I, Kim P, et al. Learning curve for endoscopic posterior cervical foraminotomy. *Eur Spine J*. 2023. Epub 2023/03/04. doi: 10.1007/s00586-023-07623-6. PubMed PMID: 36867253.
  38. Friedman GN, Grannan BL, Zinzowadia A, Williams ZM, Coumans JV. Congenitally Fused Cervical Spine Is Associated With Adjacent-Level Degeneration in the Absence of Cervical Spine Surgery. *Neurosurgery*. 2023;93(2):409-18. Epub 2023/03/10. doi: 10.1227/neu.0000000000002426. PubMed PMID: 36892290; PubMed Central PMCID: PMC9910319372.
  39. Berl MM, Koop JJ, Ailion A, Bearden DJ, Boyer K, Cooper CM, et al. Leveraging expertise and optimizing clinical research: Initial success of a pediatric epilepsy surgery collaborative. *Epilepsia*. 2023;64(6):1554-67. Epub 2023/03/11. doi: 10.1111/epi.17579. PubMed PMID: 36897767.
  40. Thirunavu V, Larkin CJ, Drumm M, Ellis EM, Roumeliotis AG, Shlobin NA, et al. Impact of Postoperative Stereotactic Body Radiation Therapy on Survival of Patients with Spinal Metastases in the Context of Additional Systemic Adjuvant Therapy. *World Neurosurg*. 2023;173:e787-e99. Epub 2023/03/13. doi: 10.1016/j.wneu.2023.03.018. PubMed PMID: 36907267.
  41. CreveCoeur TS, Alexiades NG, Bonfield CM, Brockmeyer DL, Browd SR, Chu J, et al. Building consensus for the medical management of children with moderate and severe acute spinal cord injury: a modified Delphi study. *J Neurosurg Spine*. 2023;1-14. Epub 2023/03/19. doi: 10.3171/2023.1.Spine221188. PubMed PMID: 36933257.
  42. Sarigul B, Bell RS, Chesnut R, Aguilera S, Buki A, Citerio G, et al. Prognostication and Goals of Care Decisions

in Severe Traumatic Brain Injury: A Survey of The Seattle International Severe Traumatic Brain Injury Consensus Conference Working Group. *J Neurotrauma*. 2023. Epub 2023/03/19. doi: 10.1089/neu.2022.0414. PubMed PMID: 36932737.

43. Lele AV, Fong CT, Newman SF, O'Reilly-Shah V, Walters AM, Athiraman U, et al. Anesthesiology Performance Improvement and Reporting Exchange (ASPIRE) Quality Metrics in Patients Undergoing Decompressive Craniectomy and Endoscopic Clot Evacuation after Spontaneous Supratentorial Intracerebral Hemorrhage: A Retrospective Observational Study. *J Neurosurg Anesthesiol*. 2023. Epub 2023/03/21. doi: 10.1097/ana.0000000000000912. PubMed PMID: 36941123.

44. Nelson LD, Temkin NR, Barber J, Brett BL, Okonkwo DO, McCrea MA, et al. Functional Recovery, Symptoms, and Quality of Life 1 to 5 Years After Traumatic Brain Injury. *JAMA Netw Open*. 2023;6(3):e233660. Epub 2023/03/21. doi: 10.1001/jamanetworkopen.2023.3660. PubMed PMID: 36939699; PubMed Central PMCID: PMC10028488  
Institutes of Health (NIH), the US Department of Defense (DoD), US Centers for Disease Control and Prevention (CDC), and the Medical College of Wisconsin (MCW) Advancing a Healthier Wisconsin Endowment outside the submitted work. Dr Brett reported receiving grants from National Institute on Aging and grants from National Institute of Neurological Disorders and Stroke (NINDS) outside the submitted work; and honoraria and travel reimbursement as conference speaker. Dr McCrea reported grants from DoD and the NIH to Medical College of Wisconsin during the conduct of the study; consulting work with Neurotrauma Sciences outside the submitted work; he reported researching funding from NIH, DoD, CDC, National Collegiate Athletics Association (NCAA), National Football League (NFL), and Abbott Laboratories paid to his institution outside the submitted work; he reported receiving book royalties from Oxford University Press; he reported service as a clinical consultant with the Milwaukee Bucks, Milwaukee Brewers, and Green Bay Packers, and as codirector of the NFL Neuropsychology Consultants without compensation. Dr Bodien reported receiving grants from Spaulding Rehabilitation Hospital and Massachusetts General Hospital both during the conduct of the study and outside the submitted work. Dr Robertson reported receiving grants from NIH, DoD, and NFL Charities during the conduct of the study. Dr Corrigan reported grants from University of California San Francisco (UCSF) during the conduct of the study; he reported receiving grant funding from National Institute on Independent Living and Rehabilitation Research, NIH, and Administration on Community Living outside the submitted work. Dr Diaz-Arrastia reported receiving grants from BrainBox, consulting work with MesoScale Discoveries Ischemix Inc, and NeurAegis, and equity held with NovaSignal outside the submitted work. Dr Manley reported receiving grant funding from DoD/Medical Technology Enterprise Consortium Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Network, grants from National Football League Scientific Advisory Board, US Department of Energy, NeuroTrauma Sciences LLC, and One Mind Funding during the conduct of the study; he reported that Abbott Laboratories has provided funding for add-in TRACK-TBI clinical studies; he reported receiving an unrestricted gift from the NFL to the UCSF Foundation to support research efforts of the TRACK-TBI NETWORK. Dr Mukherjee reported grants from NIH and DoD during the conduct of the study; in addition, Dr Mukherjee had a patent (No. USPTO 62/269778) issued to the University of California Regents. Dr Ngwenya reported grants from Abbott Laboratories and grants from Biogen outside the submitted work. Dr Schneider reported serving as associate editor for Neurology, and grants from NIH/NINDS and DoD outside the submitted work. Dr Yuh reported receiving grants from NIH and grants from DoD during the conduct of the study; in addition, Dr Yuh had a patent (No. US PTO 62/269778) issued to University of California Regents. Dr Zafonte reported receiving royalties from Springer/Demos publishing for serving as coeditor of text Brain Injury Medicine. Dr Zafonte serves on the scientific advisory board of Myomo, Kisbee, and NanoDiagnostics. He reported receives funding from the NIH and the DOD. He reported service as principal investigator on a grant entitled the Football Players Health Study at Harvard University, which is funded by the NFL Players Association, and he also evaluates patients in the MGH Brain and Body-TRUST Program, which is funded by the NFL Players Association. Dr Zafonte also evaluates patients for the Massachusetts General Hospital Brain and Body TRUST Center, sponsored in part by the NFLPA, and serves on the Mackey White health committee. No other disclosures were reported.

45. Hohenschurz-Schmidt DJ, Cherkin D, Rice ASC, Dworkin RH, Turk DC, McDermott MP, et al. Research objectives and general considerations for pragmatic clinical trials of pain treatments: IMMPACT statement. *Pain*. 2023;164(7):1457-72. Epub 2023/03/22. doi: 10.1097/j.pain.0000000000002888. PubMed PMID: 36943273; PubMed Central PMCID: PMC10281023 meeting and in drafting the manuscript. The project was supported by ACTION, a public-private partnership. The views expressed in this article are those of the authors and no official endorsement by the Food and Drug Administration (FDA) or the pharmaceutical and device companies that provided unrestricted grants to support the activities of the ACTION public-private partnership should be inferred. Individual authors' declarations of potential conflicts of interest are as follows: M. J. Bair reports grants or contracts from VA Health

Services Research and Development, VA Cooperative Studies Program, and National Endowment for the Arts and participation on a Data Safety Monitoring Board or Advisory Board on a NIH project conducted at the University of Utah. This trial is a pragmatic trial of physical therapy intervention. Prof Cherkin reports being paid an honorarium for mentoring the first author with manuscript writing. L. L. DeBar reports support for the present manuscript from Kaiser Permanente Washington Health Research Institute (KPWHRI); grants and contracts from National Institutes of Health (NIH) and Patient-Centered Outcomes Research Institute (PCORI); an honorarium for a lecture at 2020 IMMPACT Consensus Meeting; support for attending meetings from KPWHRI and NIH; and participation on a Data Safety Monitoring Board or Advisory Board for NCCIH, BACPAC DSMB. P. Cowan is the co-founder and secretary of the World Patients Alliance and Board Member Emeritus as well as Founder of the American Chronic Pain Association. P. Desjardins reports grants or contracts from the NIH/NIDCR Opioid Analgesic Reduction Study as co-investigator; consulting fees from Acadia Pharmaceuticals, GlaxoSmithKline Consumer Healthcare, Neurana Pharmaceuticals, Bayer Consumer Healthcare, Senju USA, Antibe Therapeutics, and CenExel; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bayer Consumer Healthcare; participation on the GSK Consumer Advisory Board; and roles on the Board of Directors of ProSelect/Coverys Medical Liability Insurance and the Board of Governors of South Orange Performing Arts Center. R. H. Dworkin has received in the past 5 years research grants and contracts from the U.S. Food and Drug Administration and the U.S. National Institutes of Health, and compensation for serving on advisory boards or consulting on clinical trial methods from Abide, Acadia, Adynxx, Analgesic Solutions, Aptinyx, Aquinox, Asahi Kasei, Astellas, Beckley, Biogen, Biohaven, Biosplice, Boston Scientific, Braeburn, Cardialen, Celgene, Centrexion, Chiesi, Chromocell, Clexio, Collegium, CombiGene, Concert, Confo, Decibel, Editas, Eli Lilly, Endo, Ethismos (equity), Eupraxia, Exicure, GlaxoSmithKline, Glenmark, Gloriana, Grace, Hope, Hospital for Special Surgery, Lotus, Mainstay, Merck, Mind Medicine (also equity), Neumentum, Neurana, NeuroBo, Novaremed, Novartis, OCT, Orion, OliPass, Pfizer, Q-State, Reckitt Benckiser, Regenacy (also equity), Sangamo, Sanifit, Scilex, Semnur, SIMR Biotech, Sinfonia, SK Biopharmaceuticals, Sollis, PRIM, Teva, Theranexus, Toray, Vertex, Vizuri, and WCG. R. R. Edwards reports no conflicts of interest. J. T Farrar reports grants or contracts from the NIH-NCATS-UL1 Grant (Co-I), FDA-BAA Contract, NIH-NIDDK-U01 Grant (Co-I), and NIH-NINDS-U24 Grant (PI); consulting fees from Lilly and Vertex Pharma; participation on a Data Safety Monitoring Board or Advisory Board for NIH-NIA(DSMB); and a role as President-Elect US-ASP. M. Ferguson reports grants or contracts from ACTION paid to her institution for work on systematic reviews and payment or honoraria for lectures at IMMPACT meetings from ACTION. R. Freeman reports consulting fees from AlgoRx, Allergan, Applied Therapeutics, Clexio, Collegium, Cutaneous NeuroDiagnostics, Glenmark, GW Pharma, GlaxoSmithKline, Eli Lilly, Lundbeck, Maxona, Novartis, NeuroBo, Regenacy, Vertex, and Worwag and stock options in Cutaneous Neurodiagnostic Life Sciences, NeuroBo, Maxona, and Regenacy. J. S. Gewandter reports grants or contracts from the NIH; consulting fees from AlgoTX, GW Pharma, Magnolia Neurosciences, Orthogonal, Science Branding Consulting, AKP Pharma, and Eikonizo and support for attending meetings or travel from SOPATE and INS. I. Gilron declares a travel stipend to attend ACTION meeting 2019 and reports consulting fees from CombiGene, GW Research, Lilly, and Novaremed. H. Grol-Prokopczyk reports grants or contracts from the National Institute on Aging of the National Institutes of Health, Award #R01AG065351; honoraria for an invited lecture for Multidisciplinary Research in Gerontology Colloquium Series, University of Southern California, and for an invited lecture at Napa Pain Conference; and travel reimbursement for travel to Napa Pain Conference. S. H. Hertz declares consulting fees from Adial Pharmaceuticals, AIXThera Operations Limited, Asahi Kasei Pharma America Corporation, Allay Pharmaceuticals, Amygdala Neurosciences, Araim Pharmaceuticals, Artugen Therapeutics, Avenue Therapeutics, BioQ Pharma, Cali Pharmaceuticals, Celero Pharma, Centrexion Therapeutics, Collegium Pharmaceutical, Concentric Analgesics, Currax Pharmaceuticals, Delpor, Domain Therapeutics, Enalare Therapeutics, Go Medical Industries, Heron Pharmaceuticals, Innocoll Biotherapeutics, Intra-Cellular Therapies, Kaleo, Lyndra Therapeutics, Maxona Pharmaceuticals, MDI Pharma, Nema Research, Neuroderm, Neumentum, Novilla Pharmaceuticals, OncoZenge, Pfizer, PleoPharma, SafeRx Pharmaceuticals, The Scripps Research Institute, Sollis Therapeutics, Sparian Biosciences, Teikoku Pharma USA, Taiwan Liposome Company, Tremereau Pharmaceuticals, Vallon Pharmaceuticals, Vizuri Health Sciences, and WinSanTor. D. G. Hohenschurz-Schmidt reports support for the present manuscript from a PhD studentship by the Alan and Sheila Diamond Charitable Trust and a honorarium from IMMPACT; a research grant from The osteopathic Foundation (paid to institution); consulting fees from Altern Health Ltd; and the role of executive committee member of the Society for Back Pain Research. S. Iyengar reports employment and travel support from the NINDS/NIH; stock options in Retiree and Eli Lilly and Company; and other financial or nonfinancial interests through employee of NINDS/NIH and adjunct senior research professor, Indiana University School of Medicine, Departments of Anesthesia and Clinical Pharmacology. C. Kamp reports support for the present manuscript from ACTION, FDA contract #HHSF223201000078C, with payments made directly to her

institution, University of Rochester Medical Center, providing 5% salary support and consulting fees from Clintrex Research Corporation (payments made to her consulting company CLKamp Consulting LLC with none of the consulting in relation to the indication of pain). B. I. Karp declares no conflict of interest. R. D. Kerns reports honoraria for presentation at the IMMPACT consensus meeting that informed this manuscript; research grants from NIH, PCORI, and VA paid to his institution; a consulting fee for a NIH-sponsored research grant; a honorarium for planning and participation in an IMMPACT consensus conference on patient engagement in clinical pain research; honoraria for participation in NIH and PCORI DSMBs and a honorarium for participation as member of Scientific Advisory Board, Chronic Pain Centre of Excellence for Canadian Veterans; an unpaid role on the Board of Directors, A Place to Nourish your Health; and an honorarium for role as the Executive Editor, Pain Medicine. B. A. Kleykamp reports income from ACTION as a full-time employee October 2018-August 2021; being the owner and principal of BAK and Associates, LLC a research and science writing consulting firm; contracts to BAK and Associates, LLC over the past 36 months include STATinMED, American Society of Addiction Medicine, ECRI, Hayes/Symplr, Pinney Associates, and Palladian Associates; payments and honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from University of Kentucky, STATinMED, Filter magazine, and Virginia Commonwealth University; support for attending meetings or travel from University of Kentucky and Virginia Commonwealth University; and a role as Communications Chair for the College on Problems of Drug Dependence. J. D. Loeser reports no conflict of interest. S. Mackey reports support for the present manuscript from the National Institutes of Health, U.S. Food and Drug Administration, Patient-Centered Outcomes Research Institute, Chris Redlich Professorship in Pain Research, and Dodie and John Rosekrans Pain Research Endowment Fund (all through Stanford University); consulting fees from Oklahoma University-Smith NIH Grant; payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Memorial Sloan Kettering Cancer Center, National Institutes of Health, Washington University, Oakstone Publishing, Comprehensive Review of Pain Medicine CME Lecture Series, Walter Reed AFB, Web-Based Lecture, Bull Publishing, George Washington University, University of Washington, Veterans Affairs, HSRD Naloxone Distribution IIR Advisory Board, Canadian Pain Society, National Institutes of Health, and New York University; support for attending meetings or travel from American Academy of Pain Medicine, American Society of Regional Anesthesia and Pain Medicine, Washington University, George Washington University, National Institutes of Health, University of Washington, U.S. Federal Drug Administration, New York University, Weill Cornell Medical College, and the International Neuromodulation Society (INS); roles on the Drug Safety and Risk Management Advisory Committee, Anesthetic and Analgesic Drug Products Advisory Committee (DSaRM/AADPAC)/(FDA) (unpaid role as Advisory Committee Member) and for HSRD Naloxone Distribution IIR Veterans Affairs (VA) (honorarium paid to himself for a role as Advisory Board Member); an unpaid role as Vice-Chair Committee on Temporomandibular Disorders for the National Academies of Sciences, National Institutes of Health, (NAS)/(NIH); other financial interests through the National Institutes of Health for T32 Postdoctoral Fellows who conduct research in laboratory; and salary supported by NIH and administered through Stanford University. R. Malamut reports no conflicts of interest. J. D. Markman declares consulting fees from Lateral Pharma, Editas, Clexio Pharma, Nektar, Pfizer, Eliem, Biogen, and Lilly; participation on Data Safety Monitoring or Advisory Boards for Regenacy Pharmaceuticals, Tonix Pharmaceuticals, and Novartis Pharmaceuticals; roles as an ex officio board member of the North American Neuromodulation Society and Treasurer of the Neuromodulation SIG of IASP; and stock options in Yellowblack Corp and Flowonix Corp. M. P. McDermott declares grants or contracts from the NIH, U.S. Food and Drug Administration, Cure SMA, and PTC Therapeutics; consulting fees from Fulcrum Therapeutics, Inc, and Neuroderm, Ltd; and participation on a Data and Safety Monitoring Board or Advisory Board for the NIH, Eli Lilly and Company, Catabasis Pharmaceuticals, Inc, Vaccinex, Inc, Neurocrine Biosciences, Inc, Voyager Therapeutics, Prilenia Therapeutics Development, Ltd, ReveraGen BioPharma, Inc, and NS Pharma, Inc. E. McNicol reports grants or contracts from ACTION paid to his institution for work on systematic reviews and payment or honoraria for lectures and attending IMMPACT meetings from ACTION. K. V. Patel reports grants and contracts from the U.S. Centers for Disease Control and Prevention and the National Institutes of Health and consultancy work for GlaxoSmithKline LLC. Prof Rice reports support for the present manuscript from IMMPACT; grants and studentships from UKRI (Medical Research Council and BBSRC), Versus Arthritis, Royal British Legion, European Commission, UK Ministry of Defence, Dr Jennie Gwynn Bequests, Alan and Sheila Diamond Trust, the British Pain Society, and the Royal Society of Medicine; consultancy and advisory board work for Imperial College Consultants, which, in the past 36 months, has included remunerated work for Confo, Vertex, PharmaNova, Lateral, Novartis, Mundipharma, Orion, Shanghai SIMR Biotech, Asahi Kasei and Toray; and lecture honoraria from MD Anderson Cancer Center, Royal Marsden Hospital, and UCSF. A. S. C. Rice is named as an inventor on patents: A. S. C. Rice, S. Vandevoorde, and D. M. Lambert Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771 and K. Okuse et al. Methods of treating pain by inhibition of vgf

activity EP13702262.0/WO2013 110945; a role as Chair of the Trial Steering Committee (TSC) for the OPTION-DM trial, National Institute for Health Research (NIHR); a role as councilor for IASP; he also was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued on the acquisition of Spinifex by Novartis in July 2015 (the final payment was made in 2019); and other interests are in the British National Formulary, Joint Committee on Vaccine and Immunisation-varicella subcommittee, Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines- Neurology, Pain, & Psychiatry Expert Advisory Group, Nonfreezing Cold Injury Independent Senior Advisory Committee (NISAC), and Royal College of Anaesthetists—Heritage and Archives Committee. M. C. Rowbotham reports consulting fees from SiteOne Therapeutics, GenEdit, and Sustained Therapeutics; payments for expert testimony from Haapala, Thompson & Abern (law firm for clinical payment to himself as medical-legal expert witness), payments from Helixmith Co, Ltd for work on a data monitoring or advisory board, and unpaid work as Treasurer of the International Association for the Study of Pain from 2020 to 2024; and holds stock options from SiteOne and CODA Biotherapeutics. F. Sandbrink reports a role as the National Program Executive Director for Pain Management, Opioid Safety, and Prescription Drug Monitoring Program, Veterans Health Administration. K. Schmader reports a grant by GSK for vaccine research, paid to his institution. D. J. Steiner reports being full-time employee of Eli Lilly and Company (Pain & Neurodegeneration). L. Simon reports consulting fees from AstraZeneca, Pfizer, Rigel, Eupraxia, Biosplice, EMDSerono, Horizon, Direct, Lilly, Kiniska, Protalix, Chemomab, TLC, SpineThera, Kyoto, PPD, Galvani, Urica, Transcode, Boehringer Ingelheim, Bristol Myers Squibb, Priovant, Roivant, Ampio, Aura, Aurinia, GSK, Xalud, Neumentum, Neema, Amzell, Applied Bio, Aptinyx, Bexson, Bone Med, Bone Therapeutics, Cancer Prevention, Cerebral Therapeutics, ChemoCentryx, Diffusion Bio, Elorac, Enalare, Foundry Therapeutics, Galapagos. Histogen, Gilead, Idera, Intravital, InGel, Kiel Labs, Mesoblast, Mpathix, Minerva, Regenosine, Samus, Sana, StageBio, Theraly, Unity, and Viridian. D. C. Turk reports royalties and licenses from Wolters Kluwer (Editor-in-Chief, *Clinical Journal of Pain*) and the American Psychological Association (Book Author); consulting fees from GSK/Novartis; and a role as Associate Director of Analgesic, Anesthetic, and Addiction Clinical Trials, Innovations, Opportunities and Networks (ACTION). C. Veasley reports no conflicts of interest. J. Vollert reports consulting fees from Vertex Pharmaceuticals, Embody Orthopaedic, and Casquar. Finally, A. D. Wasan reports no conflicts of interest.

46. Pan J, Bonow RH. Intracranial Pressure Monitors in Patients With Penetrating Brain Injury. *JAMA Netw Open*. 2023;6(3):e236754. Epub 2023/03/25. doi: 10.1001/jamanetworkopen.2023.6754. PubMed PMID: 36961469.

47. Anadani M, Almallouhi E, Maier I, Al Kasab S, Jabbour P, Kim JT, et al. Effect of intravenous thrombolysis before endovascular therapy on outcomes in patients with large core infarct. *J Neurointerv Surg*. 2023. Epub 2023/03/30. doi: 10.1136/jnis-2022-019537. PubMed PMID: 36990690.